Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

CASI Pharma Signs Up CR Guokang Pharma to Distribute Evomela in China

publication date: Mar 13, 2019

CASI, a US-Beijing pharma, out-licensed China marketing rights for Evomela® (melphalan hydrochloride for injection) in China to China Resources Guokang Pharma. In December 2018, Evomela® was approved in China for two multiple myeloma conditions following NMPA priority review. Terms of the agreement were not disclosed. Previously Melphalan was not available for multiple myeloma patients in China. CASI acquired China rights to the drug from US-based Spectrum in 2014 as part of a three drug deal. More details....

Stock Symbol: (NSDQ: CASI)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

ChinaBio® Events

ChinaBio Partnering Forum 2020

Content Availbalble Until Dec. 21, 2020